Services-Home Health Care Services
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and others; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Discounted Cash Flow Valuation of Option Care Health, Inc.
Growth
%
%
Discount
%
%
Multiple
g\r | +10% | +11% | +12% | +13% | +14% |
---|---|---|---|---|---|
0% | 10 | 9 | 8 | 8 | 7 |
+1% | 11 | 10 | 9 | 8 | 8 |
+2% | 13 | 11 | 10 | 9 | 8 |
+3% | 14 | 13 | 11 | 10 | 9 |
+4% | 17 | 14 | 12 | 11 | 10 |
Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF | $323.6M | $420.6M | $535.1M | $665.9M | $810.2M | $963.3M | $1.118B | $1.268B | $1.401B | $1.51B | $1.586B | $15.86B |
DCF | $365.8M | $404.6M | $437.9M | $463.2M | $478.9M | $483.5M | $476.5M | $458.1M | $429.3M | $392M | $3.92B | |
Value | $8.31B |
In the chart Earnings are multiplied by this value.
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
Years | 12-2014 | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Net Margin | -15% | -32% | -5.4% | -9.1% | -8.9% | -3.3% | -0.27% | 4.1% | 3.8% | 6.1% |
ROA | -11% | -53% | -1.8% | 0.37% | 8.3% | -0.012% | 4.2% | 6.8% | 7.7% | 11% |
ROE | -68% | 380% | 160% | 88% | 44% | -8.4% | -0.8% | 12% | 11% | 18% |
The average Net Margin over the past 5 years is -2.27%.
The trend of Net Margin over the past 5 years is +3.04%.
The average ROA over the past 5 years is +4.57%.
The trend of ROA over the past 5 years is +1.04%.
The average ROE over the past 5 years is +24.15%.
The trend of ROE over the past 5 years is -13.48%.
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
Years | 12-2014 | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Debt FCF | - | - | - | - | -11.74 | 120.49 | 11.65 | 6.05 | 4.74 | 3.39 |
Debt Equity | 1.98 | -5.71 | -15.41 | -5.95 | -3.77 | 1.48 | 1.15 | 0.94 | 0.79 | 0.76 |
MIN | ||||||||||
Graham Stability | - | - | - | - | - | - | - | - | 100% | 100% |
The Debt/FCF trailing twelve month is 3.39.
The trend of Debt/FCF over the past 5 years is -8.15.
Graham’s Stability measure stands at 1.00.
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
Years | 12-2015 | 12-2017 | 12-2019 | 12-2021 | Trend |
---|---|---|---|---|---|
Revenue | 22% | 37% | 20% | 15% | 5.7% |
Net Income | - | - | - | 7.6% | - |
Stockholders Equity | - | - | 15% | 18% | 7.5% |
FCF | - | - | 170% | 27% | -390% |
The Revenue CAGR over the past 5 years is +37.01%.
The trend of Revenue growth rate over the past 5 years is +5.71%.
The Earnings CAGR over the past 5 years is -.
The trend of Earnings growth rate over the past 5 years is -.
The Equity CAGR over the past 5 years is -.
The trend of Equity growth rate over the past 5 years is +7.48%.
The FCF CAGR over the past 5 years is -.
The trend of FCF growth rate over the past 5 years is -386.28%.